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Molecular determinants regulating the activation
of class B G-protein-coupled receptors (GPCRs)
by native peptide agonists are largely unknown.
We have investigated here the interaction between
the corticotropin releasing factor receptor type 1
(CRF1R) and its native 40-mer peptide ligand Urocor-
tin-I directly in mammalian cells. By incorporating
unnatural amino acid photochemical and new click-
chemical probes into the intact receptor expressed
in the native membrane of live cells, 44 intermolec-
ular spatial constraints have been derived for the
ligand-receptor interaction. The data were analyzed
in the context of the recently resolved crystal struc-
ture of CRF1R transmembrane domain and existing
extracellular domain structures, yielding a complete
conformational model for the peptide-receptor com-
plex. Structural features of the receptor-ligand com-
plex yield molecular insights on the mechanism of
receptor activation and the basis for discrimination
between agonist and antagonist function.
INTRODUCTION
G-protein-coupled receptors (GPCRs) comprise a superfamily of
eukaryotic transmembrane proteins that are critical for the con-
version of a vast array of extracellular signals into intracellular re-
sponses. Because of their key role in the regulation of major
physiological and pathophysiological functions in living organ-
isms, GPCRs are highly relevant targets for pharmacological
intervention. To that end, it is of fundamental importance to ac-
quire structural information of GPCRs and to understand how
they interact with their cognate ligands at the molecular level.
GPCRs consist of a bundle of seven transmembrane (7TM) heli-
ces connected by intracellular (ICLs) and extracellular loops
(ECLs), flanked by an N-terminal extracellular domain (ECD)
and a C-terminal cytosolic tail. Despite the impressive develop-1258 Cell 155, 1258–1269, December 5, 2013 ª2013 Elsevier Inc.ment of GPCR crystallography techniques over the last few
years, full-length structures have been solved only for class A
GPCRs mostly bound to small-molecule ligands (Katritch et al.,
2013). Only two receptors have been characterized so far in
complex with peptide ligands, both of short length (White
et al., 2012; Wu et al., 2010).
Class B GPCRs are a family of 15 peptide receptors of high
pharmacological relevance to widespread diseases, such as
diabetes (glucagon and glucagon-like peptide-1 [GLP1] recep-
tors) and osteoporosis (parathyroid hormone [PTH] receptor
and calcitonin receptor) (Pal et al., 2012). Class B GPCRs have
large ECDs (100–160 amino acids), which serve as major sites
for selective recognition of peptide ligands. Structural data for
class B receptors are limited to partial domains, including the
structures of several ligand-bound ECDs and the two very recent
structures of the 7TMdomains of the corticotropin-releasing fac-
tor receptor type 1 (CRF1R) and the glucagon receptor (GCGR),
both of which lack the ECD and are bound to small-molecule an-
tagonists (Hollenstein et al., 2013; Siu et al., 2013). Although a
conserved pattern has been identified for binding of the C-termi-
nal segments of peptide ligands to the ECDs of class B GPCRs,
little is known about how the ligand’s N terminus interacts with
the receptor’s 7TM domain to trigger downstream signaling
events (Pal et al., 2012; Parthier et al., 2009). By modulating
the basal and stress-induced secretion of adrenocorticotropic
hormone, b-endorphin, and other proopiomelanocortin-related
peptides from the anterior pituitary, CRF1R acts as the key regu-
lator of an organism’s response to stress stimuli. Molecules
antagonizing CRF1R activity have been long sought after for
the treatment of chronic stress, anxiety, and depression (Hemley
et al., 2007). Understanding how native peptide ligands activate
CRF1R can provide precious leads for the development of novel
effective therapeutics.
Ligand-receptor interactions at class B receptors have been
intensively investigated with conventional photoaffinity cross-
linking (Dong et al., 2011; Pham and Sexton, 2004; Wittels-
berger et al., 2006). In the past, photoactivatable moieties could
be inserted into peptide ligands only, which often affects their
native binding and pharmacological properties (Beyermann
et al., 2007) and limits the study to a few tolerant sites—lacking
Figure 1. Photocrosslinking of Unmodified Ucn1 with Azi-CRF1R Mutants Expressed in Mammalian Cells
(A) Schematic illustration of the photocrosslinking strategy. Receptor mutants containing the photoactivatable Uaa Azi (yellow star) are expressed in cells and
incubated with the native ligand. Upon light activation, the ligand is covalently captured by the receptor only if Azi lies in its proximity.
(B) Photoactivation of Azi by UV light. The formed nitrene inserts unspecifically in C-H and heteroatom-H bonds within an estimated radius of3 A˚ (i.e., 9 A˚ from
the Cb of Azi) (Grunbeck et al., 2012) (see also Figure S4B).
(C) Plasmids for expression of Azi-CRF1R mutants in mammalian cells. Azi is incorporated in response to a TAG codon substituted into the receptor gene. The
monomeric cassette for tRNA expression is shown under pIre-Azi3. The tRNA Bst-Yam gene is flanked by the U6 promoter and a 30 flanking sequence for correct
processing in mammalian cells (Wang et al., 2007).
(D) Amino acid sequences of selected CRF1R ligands. All peptides are C-terminally amidated. Ucn1 and CRF are endogenous agonists in human and rat; Svg
(Sauvagine) is the frog homolog. Ast (Astressin) is a synthetic antagonist derived from CRF, containing D-Phe (f), norleucine (X), and a lactam bridge (black line).
(E) Specific crosslinking of native Ucn1 by N123Azi-CRF1R. WB of cell lysates resolved by SDS-PAGE probed with aUcn1 antibody (left) to detect the ligand
covalently crosslinked to the receptor and with aFlag antibody (right) to detect the receptor containing a C-terminal Flag tag. Fully glycosylated CRF1R (mature
form at the cell membrane) runs at apparent MW 65–75 kDa. The narrower band at 50 kDa represents the high-mannose glycosylated receptor not yet
exported to the surface (Coin et al., 2011). Nonglycosylated CRF1R runs at apparent 37 kDa. The asterisk denotes one-third total protein loaded; the double
asterisk denotes sample deglycosylated with Peptide N-Glycosidase F (PNGaseF).
See also Figure S1.data especially in the 7TM region in which receptor activation
takes place (Figure S1 available online). We have recently
demonstrated that the genetic incorporation of photocrosslink-
ing amino acids into the GPCR itself is well tolerated at many
sites and allows specific crosslinking of peptide ligands (Coin
et al., 2011). We report here a systematic investigation of the
interaction between CRF1R and one of its native ligands, the
40-mer neuropeptide Urocortin-I (Ucn1) (Vaughan et al., 1995),
based on the systematic genetic incorporation of photochem-
ical and click-chemical probes into the receptor. We have
revealed the binding path of the peptide agonist in the 7TM
domain and have identified hallmarks of structural elements of
CRF1R from the native environment of the live cell. A detailed
conformational model for the CRF1R-Ucn1 complex based on
the many ligand-receptor interactions determined here eventu-
ally revealed unique features of peptide ligand binding to class
B GPCRs and provided new insights into the potential mecha-
nism for receptor activation.RESULTS
Mapping the Ucn1 Binding Interface on CRF1R via
Photocrosslinking in Live Cells
Our strategy to map the ligand-receptor interface directly in
mammalian cells is to genetically incorporate a photocrosslink-
ing unnatural amino acid (Uaa) into the receptor at each position
throughout the putative domain of interaction. If the ligand
is proximal to the Uaa in the associated complex, it is cova-
lently captured by the crosslinking moiety upon UV irradiation
and can be detected in correspondence of the molecular
weight (MW) of the receptor-ligand adduct in western blot (WB)
(Figure 1A).
We have previously incorporated the photocrosslinking Uaa
p-azido-phenylalanine (Azi, Figure 1B) into CRF1R expressed
in HEK293T cells in response to the amber stop codon TAG us-
ing an amber suppressor tRNA derived from E. coli tRNATyr and
an enhanced synthetase (E2AziRS) specific for Azi (TakimotoCell 155, 1258–1269, December 5, 2013 ª2013 Elsevier Inc. 1259
et al., 2009). This system permitted photocrosslinking experi-
ments with CRF1Rmutants containing Azi in the ECD but yielded
very low Azi incorporation in other receptor regions (Coin et al.,
2011). We devised here a more efficient system in which the
amber suppressor tRNA derived from B. stearothermophylus
tRNATyr (Bst-Yam) (Sakamoto et al., 2002) was driven by the
type 3 polymerase III promoter U6 (Wang et al., 2007). Three
tandem repeats of the tRNA cassette were built into a plasmid
coexpressing E2AziRS (Figure 1C), which was cotransfected
into HEK293T cells with a second plasmid expressing CRF1R
fused to a Flag tag at its tolerant C terminus (Coin et al., 2011).
We achieved yields of Azi-CRF1R mutants up to 30% of
wild-type (WT) (Figure 1E, lanes 10 and 12), corresponding to
the intrinsic efficiency limit for stop codon suppression (Saka-
moto et al., 2002).
Intact cells expressing the Azi-CRF1R were incubated
with unmodified CRF1R agonist Ucn1 (Figure 1D) and were
irradiated at the binding equilibrium with UV light (365 nm).
Crosslinked samples were resolved with SDS-PAGE and immu-
noblotted with an aUcn1 antibody. A distinct Ucn1-specific
band at the MW corresponding to the receptor-ligand adduct
was detected for a crosslinking hit N123Azi-CRF1R (Figure 1E,
lane 6). To demonstrate that only specifically bound Ucn1 is
captured by Azi, the CRF1R antagonist Ast (Figure 1D) (Gulyas
et al., 1995) was added as a competing ligand. The crosslinking
signal decreased gradually with increasing amounts of Ast and
disappeared when a 100-fold excess of competitor was
applied (Figure 1E, lanes 6–9). Cells expressing WT CRF1R
and nontransfected cells irradiated in the presence of Ucn1
did not give detectable crosslinking bands (Figure 1E, lanes
1–2). Likewise, no crosslinking was observed either in the
absence of ligand or when omitting UV irradiation (Figure 1E,
lanes 3–4).
With the improved expression system, we were able to incor-
porate Azi systematically throughout all positions of the juxta-
membrane region (J region) of CRF1R, including the three
ECLs and the extracellular halves of the TM helices, as well as
the hinge region joining helix I to the ECD (Figure 2C). As a con-
trol, we also tested a subset of positions in the ECD, chosen on
the basis of ECD structures (Pioszak et al., 2008; Grace et al.,
2010; Pal et al., 2010). Throughout the whole set of 145 receptor
mutants, only 6 mutants (D49ECD, N1662.61, A1863.27, R1893.30,
T2013.42, and G3567.50) gave no detectable band in WB (Fig-
ure 2C; superscript shows residue location with class BWootten
numbering for TM domains in X.YY format; see also Table S1)
(Wootten et al., 2013).
We detected Ucn1-specific bands at the MW of the receptor-
ligand adduct for 35 mutants, indicating that Ucn1 crosslinked at
these receptor sites (Figure 2A). Crosslinking was identified at
Y73 in the ECD, as previously observed using a radiolabeled
Ucn1 analog (Coin et al., 2011). In the TM region, clusters of three
to four crosslinking sites were identified at the tips of all helices
except helix IV, mostly at an interval of three to four residues (Fig-
ure 3A). The same pattern was observed at the tip of helix I
through the hinge region from N1231.43 to K1131.33, followed
by three adjacent hits at K111-K110-E109. Crosslinking sites
were also found in ECL2 and ECL3, with K262ECL2 giving a
particularly intense signal.1260 Cell 155, 1258–1269, December 5, 2013 ª2013 Elsevier Inc.As a further control, we evaluated the binding properties of
all Azi-CRF1R mutants using a photolabeling reaction with
Bpa12-Ucn1, a Ucn1 analog that contains the photocrosslink-
ing p-benzoyl-phenylalanine (Bpa) and binds to CRF1R with
high affinity (Kraetke et al., 2005). Most Azi mutants were
labeled by Bpa12-Ucn1 in a comparable range of intensity,
with only two mutants (I51ECD and V97ECD) giving no detect-
able labeling (Figure 2B). Positive labeling by Bpa12-Ucn1 as-
sesses that, for most Azi-CRF1R mutants that did not capture
Ucn1, lack of crosslinking was not due to deficiency of ligand
binding.
Overall, the photocrosslinking results provide an unprece-
dented panoramic map of the receptor regions coming in prox-
imity of the bound ligand (Figure 3A), which comprises partial
binding regions inferred from previous mutagenesis studies
(Figure S2B). To gain a 3D overview of the ligand binding path,
we highlighted the 35 crosslinking positions on the structure of
the 7TM domain of CRF1R (Figures 3B–3E) (Hollenstein et al.,
2013). The 35 hits are distributed along the J region not only at
the level of the ECLs but also as deep as two to three helix turns
down the 7TM helices, thus delimiting a relatively deep and very
broad binding pocket, which spreads across the whole space
enclosed in the TM helix bundle.
Determining the Position of Ucn1 in CRF1R via
Proximity-Enabled Chemical Crosslinking
To position Ucn1 in the 7TM binding pocket, we sought to
pinpoint specific pairs of ligand and receptor residues proximal
to each other. Intermolecular proximity points can be derived
through disulfide bond formation between Cys residues intro-
duced into both the ligand and the receptor (disulfide trapping)
(Dong et al., 2012; Monaghan et al., 2008). The disulfide
linkage, however, does not survive the reducing condition in
SDS-PAGE analysis, which was necessary to achieve complete
separation of noncrosslinked Ucn1 from the reaction mixture
(Figure S3A). We have recently demonstrated a biocompatible
click reaction between Cys and the Uaa p-20-fluoroacetyl-
phenylalanine (Ffact) (Xiang et al., 2013), which takes place
only when the two residues are in close reciprocal proximity
and forms a covalent bond stable in reducing SDS-PAGE
(Figure 4A). Here, we determined points of proximity between
Ffact incorporated into the receptor and Cys introduced into
the ligand (Figure 4B).
Ffact was incorporated into CRF1R at the 23 sites that yielded
the most intense signals in Azi-photocrosslinking. Cys was intro-
duced into Ucn1 by substituting the hydrophilic residues at sites
6, 8, 10, 12, and 14 based on the following considerations: (1) the
activation determinants of Ucn1 are included in the segment
5–16, which is expected to interact with the 7TM of the receptor
(Beyermann et al., 2000; Nielsen et al., 2000; Rivier et al., 1983);
and (2) within the alternating hydrophilic-hydrophobic amino
acid pattern of this segment (Figure 1D), substitution of the
hydrophobic residues with Ala almost abolishes ligand activity,
whereas hydrophilic residues are relatively tolerant (Kornreich
et al., 1992). To assess whether Cys6-, Cys8-, Cys10-, Cys12-,
and Cys14-Ucn1 bind CRF1R, the analogs were applied to three
receptor mutants bearing Azi in different domains (Y73Azi-,
Y116Azi-, and K262Azi-CRF1R) for Azi-photocrosslinking.
Figure 2. Mapping the Ucn1 Binding Sites onto CRF1R via Azi-Mediated Photocrosslinking
Western blots of whole-cell lysates resolved by SDS-PAGE are shown. Each block is dedicated to one receptor section with themutated positions reported at the
top. Samples in (A) and (B) were deglycosylated with PNGaseF to achieve sharper and clearer bands.
(A) Photocrosslinking of Azi-CRF1R mutants with Ucn1. Bands detected with the aUcn1 antibody reveal receptor positions at which Azi captured the native
ligand. The noncrosslinked ligand was completely separated during SDS-PAGE and was not detected (MW 4 kDa).
(B) Labeling of Azi-CRF1R with Bpa12-Ucn1. Bands detected by aUcn1 antibody show that Azi incorporation at the indicated site in CRF1R did not abolish Ucn1
binding.
(C) Nondeglycosylated samples. The expression level of the mutant Azi receptors is estimated with an antibody targeting the Flag tag fused at the C terminus of
CRF1R.
See also Table S1.
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Figure 3. Map and 3D Representation of the
Ucn1 Binding Pocket of CRF1R Based on
Azi-Photocrosslinking Data
(A) Snake plot of rat CRF1R with TM domains
based on the CRF1R crystal structure (Hollenstein
et al., 2013). ‘‘Y’’ denotes glycosylated residues.
Bold squares highlight the most conserved resi-
dues through class B GPCRs (Wootten et al.,
2013). Red circles represent residues substituted
by Azi; full magenta circles represent crosslinking
hits, with the color shades roughly reflecting the
intensity of the crosslinking bands detected in WB
with the aUcn1 antibody. Azi-CRF1R mutants that
were either not expressed at all or not labeled by
Bpa12-Ucn1 are represented with full gray circles,
whereas mutants that were poorly expressed or
weakly labeled by Bpa12-Ucn1 are represented
with half gray circles. Positions 33, 42, 51, 65, 71,
73, 77, 84, 93, 99, 116, and 270 were investigated
with radiolabeled ligands in (Coin et al., 2011).
(B–E) The crystal structure of the 7TM domain of
CRF1R (Hollenstein et al., 2013) with Azi-cross-
linking hits colored magenta. Shown are an over-
view of the domain from the membrane side (B), a
view of the receptor surface from the extracellular
space (D), and two side views of the pocket sur-
face in the membrane plane, placing in the fore-
ground helices II, III, IV, and V (C) and helices VI
and VII (E). The receptor surface in (C) and (E) is
clipped in front to allow a view inside the binding
pocket.
See also Figure S2.Indeed, all five ligands produced crosslinking bands of similar
intensity to that of WT Ucn1 with all three receptor mutants
(Figure S3B).
Intact HEK293T cells expressing each Ffact-CRF1R
mutant were incubated with each Cys-Ucn1 analog for a total
of 115 combinations. Cell lysates were resolved on SDS-1262 Cell 155, 1258–1269, December 5, 2013 ª2013 Elsevier Inc.PAGE under reducing conditions
(100 mM dithiothreitol) and analyzed
with immunoblotting. To normalize the
click-reaction results with respect to
the expression level and the binding
properties of the Ffact-CRF1R mutants,
each mutant was also photolabeled
with Bpa12-Ucn1. The intensity of the
photolabeling band was used as a stan-
dard to discriminate between hits of
the Cys-Ffact click reaction (comparable
intensity) and background signals (inten-
sity < 1/10).
Each Cys-Ucn1 analog reacted with a
subset of Ffact-CRF1R mutants (Figures
4C and 4D). The results locate position 8
of the ligand at the receptor interface
between helices V and VI, position 12
at the interface between helices VI and
VII, and position 14 close to S3497.43 in
helix VII. This pattern clearly revealsthat the ligand is oriented in the C to N direction stretching
from helix I to VI (Figure 4B). No intense signals were detected
with Cys6- or Cys10-Ucn1. Given that the alkyl C-S bond is
1.8 A˚ in length and the Ffact moiety is about 6.8 A˚, we esti-
mated the maximal Cb-Cb distance for the Cys-Ffact pairs
undergoing the click reaction to be 9 A˚ (Figure S4A).
Figure 4. Determining Ucn1 Position in CRF1R Using a Residue-Specific Chemical Crosslinking Method
(A) Chemical mechanism of the proximity-enabled click reaction between Ffact and Cys. Nucleophilic substitution by thiol group of Cys at the electropositive
carbon of Ffact results in a stable thioether bond.
(B) Chemical crosslinking between Ffact-CRF1R mutants and Cys-Ucn1 analogs. The click reaction occurs only when Cys (orange circle) and Ffact (blue circle)
residues come in close reciprocal proximity within the ligand-receptor complex.
(C) Western blots of whole-cell lysates resolved by SDS-PAGE and probed with aUcn1 antibody. Each receptor mutant (indicated in each panel) was incubated
with five Ucn1 analogs bearing Cys at the position designated in the upper string. The first lane (*) in each panel represents the control photolabeling with Bpa12-
Ucn1. Bands at MW65–75 kDa correspond to the glycosylated receptor-ligand covalent adduct.
(D) Summary of proximity points. The snake plots represent segment 1–15 of Ucn1 (above) and portions of TM domains of CRF1R. Pairs of residues giving
Cys-Ffact crosslinking are marked with the same color.
See also Figure S3.A 3D Model for Ucn1 Binding to CRF1R Supported by
Numerous Experimental Constraints
The nine spatial constraints between specific residue pairs in
CRF1R and Ucn1 derived from the Cys-Ffact click experiments
(Table 1) were used in energy-based conformational modeling.
Rat Ucn1 was docked into a flexible model of rat CRF1R gener-
ated by combining the crystal structures of human CRF1R ECD
(Protein Data Bank [PDB]: 3EHU) (Pioszak et al., 2008; Pal et al.,
2010) and of the thermostabilized human CRF1R 7TM domain
(PDB: 4K5Y) (Hollenstein et al., 2013). The two structural do-
mains were connected by a flexible linker comprising residues
103–116. Of those, residues 112–116 were modeled as a helix
analogous to the ‘‘stalk’’ region described in the crystal structure
of the closely related receptor GCGR (Siu et al., 2013).
Ligandsof theCRF family haveahighpropensity to assumehe-
lical conformation, as observed in nuclear magnetic resonance
(NMR) studies of unbound Ucn1 and CRF (Grace et al., 2007;
Romier et al., 1993) and inferred by studies on functional proper-
ties of CRF-related ligands (Beyermann et al., 2000; Rivier et al.,
1998). However, the finding that both Cys12- and Cys14-Ucn1
reacted with S349Ffact-CRF1R (Figure 4C) implies that bothpositions of the ligand point toward S3497.43 in helix VII, a condi-
tion that cannot be satisfiedwithin an a helix. Therefore, we intro-
duced full backbone flexibility in residues 11–19 of Ucn1 during
the docking procedure. Subsequent energy optimization of the
complex included flexibility in all residues of the ligand and
removed all distance restraints.
In the resulting energy-optimized docking model, most resi-
dues of the Ucn1 peptide retain the expected a-helical confor-
mation. All the imposed constraints from the Cys-Ffact reaction
are satisfied—the eight distances between Cb atoms of the
amino acid pairs are less than 9 A˚, and one is 9.4 A˚ (Table 1
and Figure S4C), which is in close agreement with the expected
value. In addition, five other proximal residue pairs in ligand
and receptor independently derived from previous crosslinking
experiments at CRF1R are well accommodated in the model,
although they were not used as constraints during the simula-
tion experiments (Table S2). The model is furthermore strongly
validated by our Azi-photocrosslinking results. All 35 cross-
linking hits lie in close proximity of the docked ligand, with
distances between Cb atoms of crosslinking sites and nonhy-
drogen atoms of Ucn1 peptide not exceeding 9 A˚ (Figure S4C),Cell 155, 1258–1269, December 5, 2013 ª2013 Elsevier Inc. 1263
Table 1. Cb-Cb Interresidue Distances Measured in the Model of
CRF1R-Ucn1 Complex
CRF1R-Ucn1 Residue Pair Cb-Cb Distance (A˚)
Q273-D8 8.6
F330-D8 4.5
L329-H12 8.0
F330-H12 5.3
N333-H12 6.9
I345-H12 8.4
N348-H12 6.5
S349-H12 9.4
S349-L14 9.0
Distances between amino acid pairs that underwent Cys-Ffact click
reaction. For each pair in modeling experiments, soft harmonic restraints
with 9 A˚ radius were imposed. See also Table S2.which is well within the estimated radius of reach of Azi
(Figure S4B).
One hallmark of the CRF1R 7TM crystal structure is a sharp
kink around G3567.50, which tilts the extracellular portion of helix
VII outward, away from the helical bundle (Hollenstein et al.,
2013) (Figures S5A and S5B). The intrinsic flexibility of the Gly
residue, high crystallographic temperature factors, and the sig-
nificant (2–3 A˚) deviations observed in the position of helix VII be-
tween the asymmetric subunits of the CRF1R crystal structure
leave open the possibility of substantial movement of the extra-
cellular portion of helix VII. Therefore, we introduced backbone
flexibility in residues Q3557.49–G3567.50 and a portion of ECL3.
In the energy-optimized model, the extracellular tip of helix VII
is indeed shifted inward by 3.1 A˚ with respect to the position
observed in the crystal structure (Figure S5C). This movement
helps to satisfy the Azi crosslinking distances for residues
R3417.35 and F3447.38 and Cys-Ffact distance for I3457.39 at
the tip of helix VII, which otherwise were in the 11–13 A˚ range.
The inward tilt also brings helix VII in closer proximity of the
ligand, significantly improving hydrophobic and polar interac-
tions between their side chains. Moreover, full conservation of
G3567.50 in class BGPCRs (Wootten et al., 2013) and intolerance
of this position to Azi substitution (Figure 2) suggest that this
point of flexibility is required for correct receptor folding and
probably plays a special role in receptor function.
Docked Ucn1 shows amajor C-terminal helical segment (V40–
T16) interacting with the ECD and the hinge region of CRF1R
(Figures 5A and 5B). The intermolecular contacts closely repro-
duce those observed in the crystal structure of CRF1R-ECD in
complex with CRF (PDB: 3EHU), including the close proximity
to Y73, which corresponds to an Azi-photocrosslinking hit. The
midregion of the ligand runs antiparallel to the linker and the
a-helical stalk of helix I (Figure 5B), which accounts for our Azi-
photocrosslinking hits at E109, K110, K111, K1131.33, and
Y1161.36. As it approaches the 7TM bundle, the ligand is about
equidistant from helix I and the tip of helix II, which corroborates
both the previously reported crosslinking of Bpa17-Svg (Sauva-
gine; Figure 1D) to H1171.37 in helix I and the crosslinking of
Bpa17-Ucn1 to the F170-E179 region in ECL1 (Assil-Kishawi
et al., 2008; Kraetke et al., 2005) (Table S2).1264 Cell 155, 1258–1269, December 5, 2013 ª2013 Elsevier Inc.As Ucn1 enters the 7TM domain in the space between helices
I, II, and VII, residues 13–15 form a short loop (Figure 5C), which
accounts for the reactions of both C12 and C14 in Ucn1 with
Ffact349 in helix VII. Following the loop, a second helical
segment (H12–S6) spans the wide TM binding pocket to reach
the interface between the extracellular end of helices V and VI
(Figure 5C). Both helical segments of Ucn1 in the model are sta-
bilized by intramolecular interactions—a salt bridge between
R15 and E19 and an H-bond between H12 and D8, as observed
in the NMR structure of the free ligand (PDB: 2RMF) (Grace
et al., 2007). A key residue in Ucn1 is H12, which interacts
extensively with residues of helix VI, ECL3, and helix VII. Indeed,
in Cys-Ffact click experiments, Cys12-Ucn1 reacted with six
CRF1R mutants bearing Ffact in these regions. At the bottom
of the 7TM pocket, the ligand reaches residues as deep as
Y1241.44, W1692.64, H1993.40, Q2735.40, L3296.55, and S3497.43
in six of the 7TM helices, respectively. The exception is helix
IV, in which no interactions with the ligand were predicted by
the model or observed by the photocrosslinking study (Figures
3A and 5C). Other residues of this Ucn1 region interact with
CRF1R loops, including the cluster of hits centered on
K262ECL2, and the stretch of residues L3296.55–N333ECL3 and
R3417.35 around ECL3 (Figure 5C).
The ligand exits the TM region through a groove between the
tips of helices V and VI, with the N terminus sticking outside the
7TM bundle (Figure 5C), which is consistent with the observation
that Ucn1 tolerates very bulky N-terminal fusions (Figure S4E).
The presence of two consecutive Pro residues at positions
3 and 4 assures an extended conformation in residues 1–5 of
Ucn1, which accounts for Azi-photocrosslinking hits in this
region (Y267ECL2, Y2705.37, and F331ECL3) pointing outside the
7TM binding pocket.
DISCUSSION
Investigation of GPCR-Ligand Interactions under Native
Conditions Using Genetically Encoded Chemical Probes
GPCRs are integral membrane proteins containing multiple
domains and various posttranslational modifications. To under-
stand GPCR-ligand interactions by crystallography, receptors
have to be extracted from the cell membrane and modified
with a series of expedients such as deglycosylation, therm-sta-
bilizing mutations, fusions with soluble proteins, or complexes
with stabilizing nanobodies. We present here a method to
investigate GPCR-ligand interactions at the intact fully post-
translationally modified receptor bound to its WT ligand on the
membrane of the live cell, which mimics the native conditions
for GPCR function. We first genetically incorporated into the re-
ceptor the photocrosslinking Uaa Azi, which served as a prox-
imity probe to provide an overall map of the ligand binding sites
on the receptor. We then determined the relative position of the
ligand in the binding pocket using a residue-specific chemical
crosslinking reaction between Ffact genetically incorporated
into the receptor and Cys introduced into the ligand. The derived
intermolecular spatial constraints served eventually to build a
detailed conformational model for the receptor-ligand complex.
Our optimized system for Uaa mutagenesis in mammalian
cells allowed incorporating the unnatural probes efficiently and
Figure 5. Conformational Model of CRF1R
Binding with Ucn1
(A) Overview of the model shows predicted inter-
action path of the Ucn1 ligand (cyan) in the re-
ceptor 7TM domain (gray) and ECD (green).
(B) Side view of the ligand binding path shows
antiparallel positions of a-helical C-terminal part of
Ucn1 and the helix I of the CRF1R that includes the
stalk region.
(C) Top view of the ligand binding pocket, showing
Ucn1 interactions with ECLs and helices of the
7TM domain. Residues that underwent the Cys-
Ffact click reaction are colored orange. Crosslinks
previously derived using Bpa-Ucn1 and Bpa-Svg
analogs (Assil-Kishawi et al., 2008; Kraetke et al.,
2005) are shown in yellow, and a disuccinimidyl
suberate (DSS) crosslink (Assil-Kishawi and Abou-
Samra, 2002) is shown in blue. Distances between
Cb atoms of crosslinked residue pairs are shown
by dashed lines with values reported in Tables 1
and S2. CRF1R residues involved in Azi photo-
crosslinking (only Ca and Cb atoms shown) are
colored magenta.
See also Figures S4 and S5.systematically throughCRF1R.Out of 145 receptormutants, only
eight were not expressed or lost the ability to bind the ligand,
yielding a 94% coverage of the screened positions. Both photo-
and chemical crosslinking hits could be distinctly identified by
immunoblotting the captured native ligand, obviating radiolabels.
Our strategy presents several advantages over traditional cross-
linking methods. By introducing the photocrosslinker into the re-
ceptor rather than into the ligand,wecould thoroughly investigate
interactions in the 7TM region, which is hardly accessible with
classic photocrosslinking experiments (Figure S1). In addition,
the Cys-Ffact crosslinking reaction takes place under reducing
conditions and is irreversible. These properties allowed working
in the presence of a reducing reagent to prevent self-dimerization
of the Cys-Ucn1 analogs and to completely separate the non-
reacted ligand on SDS-PAGE.
Given the dynamic nature of ligand-receptor interactions, our
Azi- and Cys-Ffact-crosslinking data likely depict a weighted
average of receptor conformations involved in different stages
of ligand binding and receptor activation. Faint crosslinkingCell 155, 1258–1269, Dsignals (e.g., K262Ffact; Figure 4C) may
represent assay background or tran-
sient conformations of the complex,
but they were clearly discriminated from
the strong signals (intensity < 1/10) and
excluded from model building. Although
models based on crosslinking data may
not achieve a true snapshot of a single
state like X-ray, they provide comple-
mentary information from a native sys-
tem that is only minimally modified with
a point mutation and on ensemble con-
formations that are valuable for under-
stating dynamics and function. Overall,
all 35 Azi crosslinking data are well satis-fied by distances between the corresponding receptor residue
and the ligand in the CRF1R-Ucn1 complex model, albeit
generated using only nine Cys-Ffact pairwise distance re-
straints. Nearly all side chains of the 35 crosslinking hits point
toward the docked ligand, except Y1241.44 and L3296.55. The
side chain of Y1241.44 can still reach Ucn1 residues located in
a wide gap between helices I and II, which explains its Azi
crosslinking; crosslinking at L3296.55 may be enabled by high
conformational plasticity of this residue region proximal to the
ECL3, which is disordered in molecules a and b of the CRF1R
crystal structure (Figure S5A). On the other hand, some residues
that lie in proximity of the docked ligand did not crosslink, which
comprise potential ‘‘false negatives’’ (Figure S4D). Many of
these residues point away from the ligand, whereas others
may have conformations favoring intrareceptor crosslinking or
solvent quenching (Coin et al., 2011). Although any crosslinking
technique can miss existing proximities, false negatives do not
impact the quality of the modeling restraints, which are based
solely on reliable positive crosslinking signals.ecember 5, 2013 ª2013 Elsevier Inc. 1265
A Model for CRF1R-Ucn1 Binding Reveals Common and
Divergent Features of Peptide Binding to Class BGPCRs
In the lack of full-length structures, there are continuous efforts
to model class B GPCRs in complex with their cognate peptide
ligands, including secretin (Dong et al., 2011, 2012), PTH (Mon-
aghan et al., 2008; Wittelsberger et al., 2006), and GLP1 (Miller
et al., 2011) receptors. Until now, such models have been limited
by both the lack of structural data and the scarcity of spatial
constraints for the critical TM region (Figure S1B).
We have generated here a full-length model for the CRF1R-
Ucn1 complex based on structural data for CRF1R and
supported by about 50 experimental restraints, including 9
Cys-Ffact-click constraints, 35 Azi-crosslinking hits, and 5 inde-
pendent restraints from the literature. The crosslinked residues
line the 7TM binding cavity, which is much larger than in class
A receptors or even in the class B receptor GCGR, allowing
CRF1R to accommodate the horizontal helical segment of the
ligand. We found both similarities and differences in the docking
modes of Ucn1 in the current study and of glucagon with GCGR
structure (Siu et al., 2013) or in the previous models of secretin
and GLP1 binding to their receptors (Dong et al., 2012; Miller
et al., 2011). Although in all these models the peptides enter
the receptor’s J region almost vertically along helix I ‘‘stalk,’’
the paths of the peptide’s N-terminal portion differ dramatically.
Glucagon, GLP1, and secretin are expected to have an extended
nonhelical stretch in residues 1–6, which places their N termini
deep in the 7TM pocket. In contrast, all CRF1R agonists have
much longer N-terminal segments, which have to maintain
partially helical conformations and further extend between extra-
cellular tips of helices V and VI to conform to the restraints
derived from Cys-Ffact crosslinking. Therefore, although pep-
tide ligands bind to the ECDs of class B receptors in a similar
fashion, our results indicate that different binding paths are fol-
lowed in the J region by peptides that have shorter N termini
(secretin and glucagon like, <30 residues) and longer ones
(CRF like, >40 residues).
Photocrosslinking Mapping of CRF1R Reveals
Structural Features of Class B GPCRs in the Live Cell
The distribution pattern of photocrosslinking hits reveals infor-
mation on structural elements of the receptor itself, unique in
that they are derived from the native cellular context. The interval
of 3–4 residues between crosslinking hits at the tip of the TM
domains is consistent with the helical conformation of these
segments observed in the CRF1R crystal structure. The lack of
crosslinking in helix IV is then consistent with the position of helix
IV at the periphery of the helical bundle observed in the crystal
structures of CRF1R and other GPCRs, with no access to the
binding pocket. Furthermore, the wide stretch of crosslinking
hits at an interval of 3–4 residues found in the hinge region sug-
gests that helix I extends above the level of other helices.
Although this region is not resolved in the structure of CRF1R,
the GCGR structure shows that helix I indeed extends up to
the globular BRIL protein that substituted for the ECD. Our
crosslinking data suggest that at least a part of this receptor
‘‘stalk’’ is present also in the ligand-bound full-length CRF1R in
the live cell and might be a structurally conserved signature of
class B GPCRs.1266 Cell 155, 1258–1269, December 5, 2013 ª2013 Elsevier Inc.A marked difference between the crystal structures of CRF1R
and GCGR, both representing receptors in an inactive state
bound to a small-molecule antagonist, is the position of the
extracellular tip of helix VII. In the CRF1R structure, the helix
VII tip is tilted outward by about 10 A˚ (Figure S5B), resulting in
a binding pocket that is toowide for theUcn1 peptide. Ourmodel
shows that a modest 3 A˚ inward tilt of helix VII around the flex-
ible G3567.50 dramatically improves the peptide fit in the pocket
by allowing formation of an extensive interaction interface with
both walls of the binding cleft. Moreover, this tilt also satisfies
the crosslinking restraints for several residues in the helix VII
tip, suggesting the possibility that a movement of the tip of helix
VII is part of the peptide binding process, whereby the peptide
stabilizes the more compact conformation.
An intriguing question for class B GPCRs concerns the orien-
tation of the ECD relative to the 7TM bundle. In our model, the
midregion of Ucn1 (approximately residues 26–16) runs antipar-
allel to the helix I stalk, with the helix-helix interaction being
well supported by Azi-crosslinking hits at intervals of three to
four residues within the stretch K1131.33–N1231.43. The three
consecutive crosslinking hits at E109-K110-K111 suggest
instead that this part of the ECD-7TM hinge assumes an
extended conformation. Interestingly, in our model, this region
of CRF1R corresponds to a modest kink in Ucn1 (residues 26–
30) (Figure 5B), which is similarly positioned to kinks observed
in NMR structures of other CRF-related ligands (Grace et al.,
2007). Overall, these results leave open the possibility for both
the ligand and the receptor to accommodate a kink at the
junction between the ECD and the receptor stalk, corroborating
the hypothesis that the orientation of the ECD depends on the
conformation of the ligand. Moreover, a series of weak cross-
linking signals visible in WB at residues 106–108 and 112
(Figure 2) supports a context of high flexibility in the whole
solvent-exposed region 106–113 of the CRF1R binding site.
CRF1R Peptide Ligands: Conservation Pattern and
Functional Insights
CRF1R from human and rodents is activated by endogenous
peptide agonists (CRF and Ucn1), as well as by peptide homo-
logs from other vertebrates (ovine CRF, carp Urotensin, frog
Sauvagine). Sequence alignment shows two highly conserved
regions in the N-terminal half (residues 3–22) and in the C termi-
nus (33–38) of the ligands (Figures 6A and 6B), whereas
the segment connecting the two conserved regions lacks any
significant conservation, as do the very N-terminal residues. In
our 3D structural model, the conserved regions of Ucn1 are
indeed involved in extensive interactions with either the ECD or
the 7TM domain of CRF1R, whereas the polar connector region
and the ligand’s N terminus are solvent exposed and have very
limited contacts with the receptor (Figure 6C), suggesting that
the nonconserved regions are not directly involved in receptor
recognition and activation. In fact, segment 21–31 of Ucn1 has
been demonstrated to play a mere structural role in keeping the
two segregated binding domains in the correct relative orienta-
tion (Beyermann et al., 2000), and a functional role has been
excluded also for the first three to four amino acids of CRF-
related peptides, which can be deleted without influencing
agonistic properties of the ligands (Rivier et al., 1983, 1984).
Figure 6. Conservation of the Sequence and Overall Binding Mode
of CRF1R Native Ligands
(A) Sequence alignment of CRF1R endogenous human (h), rat (r), and mouse
(m) ligands Urocortin-1 (UCN1), carp Urotensin (cUTS), ovine and human CRF
(o/hCRF), and frog Sauvagine (fSVG). Nonconserved regions are highlighted
by red boxes. The red cylinders under the alignment show the helical segments
of Ucn1 in our model.
(B) NMR structure of hUCN1 (PDB: 2RMF) in solution (Grace et al., 2007)
shows its propensity to form an a-helical fold. The nonconserved regions are
colored red.
(C) Side view of the ligand binding path in our model of CRF1R-Ucn1. CRF1R
is colored green in ECD and yellow in the hinge and 7TM region. The non-
conserved regions of Ucn1 are colored red with side chains shown.
See also Figures S4 and S5.Instead, from position 6 of CRF on, N-terminal truncations
gradually reduce potency and activity of the agonist, eventually
converting it into an antagonist with the deletion of residue 8,
thus identifying segment 6–8 as crucial to achieve receptor acti-
vation (Rivier et al., 1984, 1998). The fact that, in our 3D model,
the corresponding residues in Ucn1 (positions 5–7) are located
in the groove between helices V and VI suggests that this inter-
action with the agonist triggers CRF1R activation, likely by
inducing a movement of the two helices that rearranges the
receptor from the unbound state to the active state. This effect
cannot be exerted by peptide antagonists because they are
too short to reach the interface between helices V and VI. Inter-
estingly, small-molecule antagonists of CRF1R have been
shown to bind in a deep TM pocket between helices III, V, and
VI, probably hampering the natural activation movement (Hoare
et al., 2006; Hollenstein et al., 2013).Conclusions
We have investigated the interaction between the CRF1R and its
native peptide ligand Ucn1 by exploiting photo- and unique
chemical reactivities of Uaas genetically incorporated into the
receptor expressed in mammalian cells. The overall result is a
detailed 3D binding model supported by about 50 experimental
constraints, which unveils the binding path of the peptide agonist
in the activation domain of the class B receptor and allows
insight into its activation mechanism. Our method represents a
major advance with respect to intrinsically limited and experi-
mentally more demanding traditional photocrosslinking ap-
proaches and provides unique panoramic information derived
from the full-length receptor in the native context of the live
cell, which complements data derived from crystallographic
characterization of isolated receptors in an artificial environment.
Because Uaa incorporation imposes no restrictions on target
sites or protein types, this strategy should be generally appli-
cable to study protein interactions under native conditions.
EXPERIMENTAL PROCEDURES
Photocrosslinking
HEK293T cells were cotransfected with plasmid pIre-Azi3 (expressing the Bst-
Yam tRNA and the E2AziRS specific for Azi) (Takimoto et al., 2009) and plasmid
xxxtag-CRF1R-Flag (expressing CRF1R) in the presence of 1 mM Azi in the
culture medium. After 48 hr, cells were harvested, and aliquots were incubated
with either 100 nM Ucn1 or Bpa12-Ucn1 for 2 hr at room temperature (RT),
followed by irradiation with a handheld UV lamp (365 nm, 8 W) for 40 min.
Cells were lysed in 1% Triton X-100 buffer. Aliquots of cell lysates were
denatured with 0.5% SDS and 400 mM DTT for 20–30 min at 37C and
deglycosylated with PNGase F at 37C for 1 hr. Both deglycosylated
and nondeglycosylated samples were resolved with denaturing SDS-PAGE
(9%–10% acrylamide) and protein transferred onto a PVDF membrane. Blots
were probed with monoclonal mouse anti-Flag M2-peroxidase conjugate
(Sigma) to detect CRF1R. A homemade polyclonal aUcn1 antibody followed
by a secondary arabbit-HRP conjugate was used to detect Ucn1. Signals
were developed with SuperSignal West Pico Chemiluminescent substrate
(Thermo Scientific).
Cys-Ffact Chemical Crosslinking
HEK293T cells were cotransfected with plasmid pIre-Keto3 (expressing the
Bst-Yam tRNA and the EKetoRS specific for Ffact) (Takimoto et al., 2009)
and plasmid xxxtag-CRF1R-Flag in the presence of 0.25 mM Ffact in the
culture medium. Cells were harvested 48 hr later and split in six aliquots.
Five aliquots were individually incubated with the five Cys-Ucn1 mutants
(100 nM) in the presence of 1 mM tris(2-carboxyethyl)phosphine for 90 min.
The sixth aliquot was incubated with 100 nM Bpa12-Ucn1 for 90 min, followed
by irradiation for 20 min in a Spectrolinker XL-1500A (365 nm) at 4,400–
5,000 mW/cm2. Samples were then processed and analyzed with WB as
described for the photocrosslinking experiments.
Modeling
Energy-based conformational modeling of the CRF1R complex with Ucn1 was
performed with ICM-Pro molecular modeling software (Molsoft LLC) based on
the crystal structures of CRF1R ECD (PDB: 3EHU) (Pioszak et al., 2008; Pal
et al., 2010) and 7TM (PDB: 4K5Y) (Hollenstein et al., 2013) domains. Regions
not defined by the crystal structures—e.g., linker connecting the ECD and 7TM
domain—or known to have high flexibility—e.g., Gly365-dependent kink
around in helix VII—were treated as fully flexible. Peptide docking and energy
optimization was guided by Ffact-CRF1R/Cys-Ucn1 chemical crosslinking
data, introduced as soft harmonic tethers between Cb atoms of the corre-
sponding residues. Global energy optimization of the complex in internal coor-
dinates (Abagyan et al., 2012) was performed by exhaustive conformational
sampling of protein backbone in the flexible regions, as well as side chainsCell 155, 1258–1269, December 5, 2013 ª2013 Elsevier Inc. 1267
of the residues lining the 7TM binding pocket of CRF1R. In the Ucn1 peptide,
conformational sampling included all potentially nonhelical regions (1 to 5, 11
to 19, and 37 to 40) and all side chains. The final optimization round of the
CRF1R complex with Ucn1 was performed with a fully flexible ligand and
without any distance restraints.
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